[Gingko biloba extract EGb 761 and pentoxifylline in intermittent claudication. Secondary analysis of the clinical effectiveness].
Clinical trials on the efficacy of EGb 761 and pentoxifylline are summarized in the context of their methods and results and compared with each other. All placebo-controlled, randomized and double-blind studies with the major target objective of "pain-free walking distance" were selected. The pentoxifylline studies were adopted from a survey of the existing literature in the English language, which has been brought up to date via DIMDI research. The studies on both active substances are fraught with similar difficulties as to method, and are not different as regards their quality. The increase in walking distance is highly variable, especially in the pentoxifylline studies. On average through each and all of the studies on both preparations, an increase of 45% (EGb 761) or 57% (pentoxifylline) in relation to initial values is here found. No differences in the documentation of efficacy and the clinical efficacy were discovered between the two substances, both of which are registered as effective substances in the treatment of peripheral arterial occlusion (pAO) in accordance with the Federal German Drugs Law (Arzneimittelgesetz, AMG) of 1976.
Letzel
H
H
Schoop
W
W
D004305:Dose-Response Relationship, Drug; D005080:Exercise Test; D020441:Ginkgo biloba; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D010431:Pentoxifylline / Q000627:therapeutic use*; D010936:Plant Extracts / Q000627:therapeutic use*; D000096983:Ginkgo Extract
D010431:Pentoxifylline; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract
Gingko-biloba-Extrakt EGb 761 und Pentoxifyllin bei Claudicatio intermittens. Sekundäranalyse zur klinischen Wirksamkeit.